Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing ...
For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., ...
Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...
Ponesimod is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. The Food and Drug Administration (FDA) has approved Ponvory™ (ponesimod; Janssen) for the treatment of ...
The appraisal committee considered evidence submitted by Novartis, and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...
A breakthrough in monkey malaria research could help scientists diagnose and treat a relapsing form of human malaria. A breakthrough in monkey malaria research by two University of Otago scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results